Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT05192304
Other study ID # BR-2020-1491-TPN672
Secondary ID
Status Not yet recruiting
Phase Phase 1
First received
Last updated
Start date February 1, 2022
Est. completion date March 1, 2024

Study information

Verified date October 2021
Source Jiangsu Kanion Pharmaceutical Co., Ltd
Contact Zhao Binjiang
Phone 86-518-85521987
Email 13466570402@163.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is a Phase Ib clinical study of TPN672 maleate in patients with schizophrenia


Description:

This is a single-center, randomized, double-blind, placebo-controlled, dosion-increasing, Phase Ib clinical study evaluating the safety, tolerability, and pharmacokinetic characteristics of multiple doses of TPN672 maleate in patients with schizophrenia


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 62
Est. completion date March 1, 2024
Est. primary completion date March 1, 2023
Accepts healthy volunteers No
Gender All
Age group 18 Years to 65 Years
Eligibility Inclusion Criteria: 1. 18 years old = age = 65 years old at the time of signing the informed consent form, male or female. 2. 18.5kg/m2 = body mass index (BMI) = 30kg/m2, and weight = 50kg for men and = 45kg for women. 3. Subjects met DSM-5 diagnostic criteria for a confirmed diagnosis of schizophrenia and were stable within the past 6 months as assessed by the investigator. 4. Subjects are currently taking aripiprazole, olanzapine or risperidone monotherapy for schizophrenia at a dose not exceeding the maximum dose specified in the instructions and the dose and frequency of administration have not changed in the last 1 month. 5. Screening period PANSS scale total score <70, PANSS scale individual score of positive symptom items =3, CGI-S score =4. 6. Individual scores were =1 on the SAS scale, =2 on the AIMS scale, and =2 on item 4 of the BARS scale, "Overall clinical assessment of sedentary inability" during the screening period. 7. Female and male subjects of childbearing potential and their spouses must be able to secure effective contraception (medically approved contraception such as IUDs, the pill or condoms) during the study and for 6 months after the end of the drug administration. 8. Subjects and their guardians fully understand the purpose and requirements of the trial, voluntarily participate in the clinical trial and sign a written informed consent form, and are willing to complete the entire trial process according to the trial requirements. Exclusion Criteria: 1. Subjects met DSM-5 criteria for other psychiatric disorders. 2. Subjects were administered strong inducers/strong inhibitors of CYP2D6, CYP3A4, CYP3A5, CYP2C9 for 5 half-lives prior to the first dose. 3. Subjects were on long-acting antipsychotics for 6 months prior to their first dose. 4. Received electroconvulsive therapy, transcranial magnetic stimulation (rTMS) within 1 month prior to screening 5. Those who answered "yes" to questions 4 or 5 of the suicidal ideation entry on the Columbia Suicide Scale (C-SSRS) during the screening period, or who were currently or within the past 12 months significantly suicidal, or who were considered to be at risk for suicidal and violent behavior based on the investigator's clinical assessment. 6. Those with abnormal physical examination or vital signs during the screening period that are clinically significant. 7. Abnormal laboratory tests during the screening period that the investigator determines to be clinically significant, e.g., liver: ALT or AST= 1.2 times the upper limit of normal; kidney: Cr> the upper limit of normal value. 8. Prolactin = 5 times the upper limit of normal during the screening period. 9. Screening subjects with systolic blood pressure <90 mmHg or >140 mmHg and diastolic blood pressure < 60mmHg or >90mmHg. 10. Patients with poorly controlled diabetes (fasting glucose = 10 mmol/L), or are On insulin for diabetes, or at screening with a primary diagnosis of type 2 diabetes. 11. Screening QTc interval >450ms (men) or 470ms (women), or family history of long QT interval syndrome, or combined cardiac insufficiency, severe arrhythmia or ischemic heart disease requiring medication, congenital heart disease, severe organic heart disease or history of such disease. 12. Combined with convulsive disorders such as epilepsy (except febrile convulsions) 13. Current or previous hyper- or hypothyroidism, Parkinson's disease, malignancy. 14. Tobacco addiction within 1 year prior to screening, with an average of >10 cigarettes or equivalent per day. 15. Alcohol consumption within 1 year prior to screening, with an average weekly intake of more than 14 units of alcohol (1 unit = 285 ml of beer or 25 ml of spirits or 150 ml of wine) or a positive breath test for alcohol. 16. Persons with a history of drug or substance abuse within 1 year prior to screening or a positive urine drug screen. 17. Subjects who may be hypersensitive to any of the components of this drug. 18. HIV antibody, HBsAg, HCV antibody or positive syphilis serology results. 19. History of significant blood loss or blood loss = 200 ml in the 3 months prior to screening 20. Enrolled in another clinical trial within 3 months prior to screening, or currently participating in a clinical trial. 21. Women who are expecting or breastfeeding. 22. The investigator did not consider it appropriate to participate in this trial.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
TPN-672
single dose of TPN-672 maleate tablet

Locations

Country Name City State
China Shanghai Mental Health Center Shanghai Shanghai

Sponsors (2)

Lead Sponsor Collaborator
Jiangsu Kanion Pharmaceutical Co., Ltd Shanghai Mental Health Center

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary Adverse events Incidence of Adverse Events follow-up visit from the beginning of the dose to the day 14 after the last dose
Primary Blood pressure Safety indicator,Blood pressure is recorded in millimeters of mercury Day 14
Primary Respiration Safety indicator,the unit of recording is the number of breaths per minute. Day 14
Primary Heart rate Safety indicator,the unit of heart rate is the number of heartbeats per minute. Day 14
Primary Temperature Safety indicator,Body temperature is recorded in degrees Celsius Day 14
Secondary Maximum plasma concentration (Cmax) Blood will be drawn from adult subjects pre-drug application and at 30min, 60min, 90min, 120min, 180min, 240min (4h), 480min (8h),720min (12h),1440min(24h). 240 hours
Secondary Time to maximum plasma concentration (Tmax) Biological sample including blood for PK will be collected at the same time point. 240 hours
Secondary Area under the curve (AUC) Biological sample including blood for PK will be collected at the same time point. 240 hours
Secondary steady state minimal concentration(Css_min) Biological sample including blood for PK will be collected at the same time point 240hours
Secondary Elimination half-life (t1/2) Biological sample including blood for PK will be collected at the same time point. 30 minutes, 1 hour, 1.5 hours, 2 hours, 3 hours, 4 hours, 8 hours, 12 hours ,days 8-14 after the last dose.
Secondary Positive and Negative Syndrome Scale The PANSS consisted of a positive scale of 7 items, a negative scale of 7 items, and a general psychopathology scale of 16 items, for a total of 30 items, and 3 supplementary items to assess the risk of attack. A 7-point scale with increasing levels of psychopathology was used: 1 nothing; 7 a very severe. Follow-up visit on the day 14 after the last dose
Secondary Clinical Global Impression sions scale The scale is divided into 1. overall assessment of disease severity 2. overall degree of improvement. The lower the score, the higher the degree of improvement of the patient. Follow-up visit on the day 14 after the last dose
Secondary Calgary Depression Scale for Schizophrenia There were 9 entries, including mood depression, feelings of hopelessness, self-deprecation, guilt implicated perceptions, pathological guilt, morning depression, early awakening, suicidality, and observed depressive manifestations. The lower the score the less severe the depressive symptoms. Follow-up visit on the day 14 after the last dose
Secondary Blood coagulation function Safety indicators, including PT,APTT Day 14
Secondary 12-lead ECG Safety indicators, including QTc Day 14
Secondary Serum prolactin ( PRL) Testing for affected hormone levels Day 14
See also
  Status Clinical Trial Phase
Recruiting NCT05039489 - A Study on the Brain Mechanism of cTBS in Improving Medication-resistant Auditory Hallucinations in Schizophrenia N/A
Completed NCT05321602 - Study to Evaluate the PK Profiles of LY03010 in Patients With Schizophrenia or Schizoaffective Disorder Phase 1
Completed NCT05111548 - Brain Stimulation and Cognitive Training - Efficacy N/A
Completed NCT04503954 - Efficacy of Chronic Disease Self-management Program in People With Schizophrenia N/A
Completed NCT02831231 - Pilot Study Comparing Effects of Xanomeline Alone to Xanomeline Plus Trospium Phase 1
Completed NCT05517460 - The Efficacy of Auricular Acupressure on Improving Constipation Among Residents in Community Rehabilitation Center N/A
Completed NCT03652974 - Disturbance of Plasma Cytokine Parameters in Clozapine-Resistant Treatment-Refractory Schizophrenia (CTRS) and Their Association With Combination Therapy Phase 4
Recruiting NCT04012684 - rTMS on Mismatch Negativity of Schizophrenia N/A
Recruiting NCT04481217 - Cognitive Factors Mediating the Relationship Between Childhood Trauma and Auditory Hallucinations in Schizophrenia N/A
Completed NCT00212784 - Efficacy and Safety of Asenapine Using an Active Control in Subjects With Schizophrenia or Schizoaffective Disorder (25517)(P05935) Phase 3
Completed NCT04092686 - A Clinical Trial That Will Study the Efficacy and Safety of an Investigational Drug in Acutely Psychotic People With Schizophrenia Phase 3
Completed NCT01914393 - Pediatric Open-Label Extension Study Phase 3
Recruiting NCT03790345 - Vitamin B6 and B12 in the Treatment of Movement Disorders Induced by Antipsychotics Phase 2/Phase 3
Recruiting NCT05956327 - Insight Into Hippocampal Neuroplasticity in Schizophrenia by Investigating Molecular Pathways During Physical Training N/A
Terminated NCT03209778 - Involuntary Memories Investigation in Schizophrenia N/A
Terminated NCT03261817 - A Controlled Study With Remote Web-based Adapted Physical Activity (e-APA) in Psychotic Disorders N/A
Completed NCT02905604 - Magnetic Stimulation of the Brain in Schizophrenia or Depression N/A
Recruiting NCT05542212 - Intra-cortical Inhibition and Cognitive Deficits in Schizophrenia N/A
Completed NCT04411979 - Effects of 12 Weeks Walking on Cognitive Function in Schizophrenia N/A
Terminated NCT03220438 - TMS Enhancement of Visual Plasticity in Schizophrenia N/A